DOCSLIB.ORG

Going Public Exposing the Silent Killer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Going Public Exposing the Silent Killer News from the Medical Research Council network Summer 2015 Leading science for better health Going public The unexpected benefits of open science Exposing the silent killer A new test that doubles ovarian cancer detection rates Network can also be downloaded as a PDF at: www.mrc.ac.uk/network CONTENTS News COMMENT FROM Academic-industry network to find new treatments 3 UK population cohorts now online 4 John People Savill CHIEF EXECUTIVE Obituary: Professor Alan Hall 9 Industry and academia have a symbiotic relationship. Discoveries made in universities and MRC institutes where Latest discoveries scientists have the freedom to pursue fundamental research Childhood obesity risk has trebled since 1946 12 questions feed into the pipeline of pharma and biotech companies. Screening method doubles ovarian cancer detection 13 And precious few new treatments and diagnostics would ever reach patients without industry’s expertise, facilities and financial muscle, which are needed to take a potential new treatment through the rigours of Funding clinical trials and regulatory approval. Working together is critical to our shared aim of improving human health. Getting best value from the MRC’s The MRC has a long track record of working with industry. infrastructure investments 14 AstraZeneca were pioneers in the first innovative compound collaboration project with the MRC in 2012. Our Stratified Medicine programme involves over 50 companies and a further six companies are involved in the MRC-led Dementia Platform UK. Features We’ve just announced our latest industry partnership: Infographic: the MRC in numbers 10 project EMINENT with GlaxoSmithKline. This is another innovation in terms of how academic scientists can work Working Life: Paediatrician and clinical trial coordinator effectively with industry partners; a network of academic and industry researchers within which ideas and new Dr Olubukola Idoko 16 knowledge can be freely and quickly exchanged and discoveries with commercial potential can be taken forward. Opinion: Going public with your research 18 Read more about EMINENT on page 3. John Savill MRC Chief Executive NEWS Academic-industry network to find new treatments Five universities have joined forces with GlaxoSmithKline in an MRC-funded network to study the underlying causes of common diseases for which there are no - or very few - treatments. The Experimental Medicine Initiative to Explore New The MRC has invested £5 million up front with the Therapies (EMINENT) brings together the Universities of possibility of a further £3m in future, depending on Cambridge, Glasgow, Imperial College, Newcastle, and a review of the project’s early outcomes. The MRC University College London with pharmaceutical company funding will support the academic costs of up to ten GlaxoSmithKline (GSK). The network of researchers will focused projects over the next five years through carry out experimental medicine studies to improve grant-like awards to the universities. understanding of the fundamental mechanisms of chronic obstructive pulmonary disease, immune Training opportunities will be provided for both early- inflammation, respiratory disease and fibrosis and career and established researchers within the network develop new treatment strategies. to help build a legacy of expertise in translational and experimental human research. GSK will openly collaborate These diseases blight the lives of millions of people to grant access to their expertise, drug portfolio and worldwide and are a leading cause of deaths, but they facilities, allowing information and new knowledge to flow stubbornly continue to have few or no treatment options freely and promptly through the network, maximising the despite the progress made in other disease areas over the impact of research discoveries. past 20 years. Find out more at www.mrc.ac.uk/news-events/news New resource for developmental biologists A new website for researchers has been launched, bringing together data on the genes responsible for developmental diseases. The website collates 3D imaging, tissue histology and immunochemistry data, as well as embryonic or placental structural abnormalities from mice for each ‘knocked out’ gene. The data are from the Wellcome Trust-funded ‘Deciphering the Mechanisms of Developmental Disorders’ (DMDD) research programme which has been running since 2013, coordinated by former MRC National Institute for Medical Research scientists who now work at the Francis Crick Institute. Set up to discover genes required for embryonic development, DMDD’s goal is to find candidate genes involved in developmental disease, and kick-start study of why these mutations have such profound effects on embryo development and survival. Visit the website at http://dmdd.org.uk MRCNetwork | 3 NEWS UK population cohorts now online A new online directory of the UK’s largest population cohorts has been created by the MRC to help researchers and policy-makers to find and use them more easily. These large-scale studies of healthy people are Professor Jill Pell, Director of the Institute of a valuable UK asset; currently one in 30 people in Health and Wellbeing at the University of Glasgow, the UK population are cohort study members. has also written a post for the MRC’s blog about the value of cohort studies. She comments: The directory provides a brief profile of each cohort “As a researcher, I think this directory will be and a high level overview of the information it invaluable in improving awareness and use of collects. Users can filter their searches by gender, these valuable resources, and I encourage the age range, sample size at recruitment and variables rest of the research community to take full collected such as physical, cognitive, lifestyle and advantage of this exciting development.” socioeconomic measures and biological samples. You can find the directory at: It currently holds information on the UK’s www.mrc.ac.uk/cohort-directory largest population cohorts but ultimately this will be expanded to include a broader range of Read Jill’s full post at http://mrc.io/1JYMBiX cohort studies. Updated guidance on animal research Those applying for funding to carry out research involving animals will now need to provide more information under revised guidance from the major UK research funders. Guidelines produced by the UK research minimised and providing information on councils and the major charitable funding the statistical aspects of the study. bodies were reviewed and updated in April so that animal research applications can be The animal research section on the Joint more robustly evaluated. Electronic Submission System (Je-S) has been altered to reflect these changes and all All proposals using animals now need to applicants for research council funding explain not only why the use of animals is involving animals should read the new justified and the ethical implications of the guidance, along with the NC3Rs’ ARRIVE planned experiments, but also clearly guidelines, before starting their application. describe how the design of experiments will give robust results. That includes outlining Download the documents at: how the number of animals to be used was http://mrc.io/1HHfXC5 decided, how experimental bias will be http://mrc.io/1G2ADPq 4 | MRCNetwork Lab-grown organs to liver tests: a look back at our successes in 2013-14 A review of some of the MRC’s successes in 2013/14 can now be found on our website, featuring interviews with scientists behind a selection of our most interesting and important discoveries. Professor Giovanna Mallucci of the MRC Toxicology Unit in Leicester, who has discovered a way to prevent neurodegeneration in mice. Professor Clare Blackburn at the MRC Professor Giovanna Mallucci The test could cut diagnosis time from Centre for Regenerative Medicine at has discovered a way to stop weeks to a single day and has potential the University of Edinburgh tells us neurodegeneration in its tracks in mice to be used across the globe. how she and her team have grown the – pointing the way to possible new first ever fully functional organ from preventative treatments for dementia. For 102 years, the MRC has targeted the cells in the lab – a thymus gland – which world’s biggest health problems, funded could ultimately provide a new way to MRC research doesn’t just benefit the very best scientists and ideas to boost immunity in those who most our health and society; it generates discover answers to those problems, need it, such as leukemia patients and innovative technologies, drugs and and used these discoveries to transform the elderly. diagnostics which create jobs and our lives. The review includes a help boost the UK economy. At the selection of success stories from the Neurodegenerative diseases such University of Oxford, Professor Stefan past two years which add to our long as dementia are one of the biggest Neubauer explains how his MRC- story of improving human health, challenges our society faces as the supported research ultimately led to him benefiting society and supporting number of elderly people in the and a group of colleagues establishing a economic growth. population grows. At the MRC new company to develop and market Toxicology Unit in Leicester, their new test for chronic liver disease. www.mrc.ac.uk/annualreview13-14 MRCNetwork | 5 NEWS Gaming technology solves twitchytwitchy patient problem MRC-funded researchers plan to use video game technology to solve the problem of blurry brain scan images which happen when patients move their heads while inside the scanner. Many patients, particularly those with dementia, find it hard or controller. By combining this with the latest advances in impossible to keep completely still during scans carried out as computer vision algorithms they will make a low cost, accurate part of their diagnosis or during research studies. The blurring and user-friendly system that integrates with PET scanners and effects caused by this movement leads to wasted or inaccurate can be widely used for diagnosis and research. No special lighting data, which is costly and inefficient.
Load more

Recommended publications
  • BSCB Newsletter 2017D
    2017 BSCB Newsletter BRITISH SOCIETY FOR CELL BIOLOGY Meet the new BSCB President Royal Opening of the Crick Meeting reports 2017 CONTENTS BSCB Newsletter News 2 Book reviews 7 Features 8 Meeting Reports 24 Summer students 30 Society Business 33 Editorial Welcome to the 2017 BSCB newsletter. After several meeting hosted several well received events for our Front cover: years of excellent service, Kate Nobes has stepped PhD and Postdoc members, which we discuss on The head of a Drosophila pupa. The developing down and handed the reins over to me. I’ve enjoyed page 5. Our PhD and Postdoc reps are working hard compound eye (green) is putting together this years’ newsletter. It’s been great to make the event bigger and better for next year! The composed of several hundred simple units called ommatidia to hear what our members have been up to, and I social events were well attended including the now arranged in an extremely hope you will enjoy reading it. infamous annual “Pub Quiz” and disco after the regular array. The giant conference dinner. Members will be relieved to know polyploidy cells of the fat body (red), the fly equivalent of the The 2016 BSCB/DB spring meeting, organised by our we aren’t including any photos from that here. mammalian liver and adipose committee members Buzz Baum (UCL), Silke tissue, occupy a big area of the Robatzek and Steve Royle, had a particular focus on In this issue, we highlight the great work the BSCB head. Cells and Tissue Architecture, Growth & Cell Division, has been doing to engage young scientists.
    [Show full text]
  • Curriculum Vitae Prof. Dr. Geoffrey L. Smith
    Curriculum Vitae Prof. Dr. Geoffrey L. Smith Name: Geoffrey L. Smith Born: 23 July 1955 Main areas of research: Microbiology, virology, immunology, vaccinia virus, vaccines Geoffrey L. Smith is a British microbiologist and virologist specialising in the area of poxviruses. His research examines the interaction of poxviruses with the infected host cell and the immune system, concentrating especially on the vaccinia virus that was the vaccine used to eradicate smallpox. His research has enabled new vaccination concepts to be developed and provided important insights into how viruses evade the host innate immune response and cause disease. Academic and Professional Career since 2011 Chair of the Pathology Department, University of Cambridge, UK and Principal Research Fellow, Wellcome Trust 2000 ‐ 2011 Director, Department of Virology, Imperial College London, UK 1989 ‐ 2000 Reader then Professor, University of Oxford, UK 1985 ‐ 1989 Lecturer in Virology, University of Cambridge, UK 1981 ‐ 1984 Postdoctoral Fellow, National Institutes of Health, Bethesda, USA 1981 PhD, National Institute for Medical Research, Mill Hill, London, UK Functions in Scientific Societies and Committees since 2015 Chair of the scientific council, Friedrich Löffler Institute 2012 ‐ 2016 Member, Biomedical Panel of the University Research Grant Committee, Hong Kong 2011 ‐ 2014 President, International Union of Microbiological Societies 2009 ‐ 2012 Chair, Royal Society Committee for Scientific Aspects of International Security Nationale Akademie der Wissenschaften Leopoldina
    [Show full text]
  • UKI NETS 11Th National Conference 25 November 2013 the Royal College of Physicians London, UK
    UKI NETS 11th National Conference 25 November 2013 The Royal College of Physicians London, UK Abstract Marking Panel Alan Anthoney (Leeds, UK) Simon Aylwin (London, UK) Dr Tu Vinh Luong (London, UK) Prakesh Manoharan (Manchester, UK) Nick Reed (Glasgow, UK) UKI NETS would like to thank their sponsors for their kind generosity: Educational Sponsors: Meeting Sponsor: UKI NETS Euro House 22 Apex Court Tel: +44-(0)1454 642277 Woodlands Fax: +44-(0)1454 642222 Bradley Stoke Email: [email protected] Bristol, BS32 4JT, UK Website: www.ukinets.org 2 Contents Pages Programme 4 – 6 Speaker Biographies 7 - 10 Abstracts 12 – 67 3 Programme CPD UKI NETS 11TH NATIONAL CONFERENCE has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 6 category 1 (external) CPD credits. 08:30 Registration, Coffee and Poster viewing 09:25 Welcome and opening remarks Nick Reed (Glasgow, UK) 09:30 – 11:00 Session 1 – Pancreatic NETS –who when and how to intervene? Chair: Graeme Poston 09:30 Imaging assessment of the incidental pancreatic mass Dylan Lewis (London, UK) 09:50 Management of pancreatic primary in presence of metastatic disease Massimo Falconi (Torrette-Ancona, Italy) 10:10 Localisation of insulinoma Karim Meeran (London, UK) 10:30 Surgical approach to the pancreas and parathyroid in patients with MEN1/VHL Barney Harrison (Sheffield, UK) 10:50 Open Floor Q&A 11:00 Coffee, poster viewing and exhibition 11:30 - 12:15 Session 2a – Management dilemmas - Debate – Chemotherapy is first line treatment for pancreatic metastatic
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • Paterson Institute for Cancer Research Scientific Report 2008 Contents
    paterson institute for cancer research scientific report 2008 cover images: Main image supplied by Karim Labib and Alberto sanchez-Diaz (cell cycle Group). Budding yeast cells lacking the inn1 protein are unable to complete cytokinesis. these cells express a fusion of a green fluorescent protein to a marker of the plasma membrane, and have red fluorescent proteins attached to components of the spindle poles and actomyosin ring (sanchez-Diaz et al., nature cell Biology 2008; 10: 395). Additional images: front cover image supplied by Helen rushton, simon Woodcock and Angeliki Malliri (cell signalling Group). the image is of a mitotic spindle in fixed MDcK (Madin-Darby canine kidney) epithelial cells, which have been stained with an anti-beta tubulin antibody (green), DApi (blue) and an anti-centromere antibody (crest, red) which recognises the kinetochores of the chromosomes. the image was taken on the spinning disk confocal microscope using a 150 x lens. rear cover image supplied by Andrei ivanov and tim illidge (targeted therapy Group). Visualisation of tubulin (green) and quadripolar mitosis (DnA stained with DApi), Burkitt’s lymphoma namalwa cell after 10 Gy irradiation. issn 1740-4525 copyright 2008 © cancer research UK Paterson Institute for Cancer Research Scientific Report 2008 Contents 4 Director’s Introduction Researchers’ pages – Paterson Institute for Cancer Research 8 Crispin Miller Applied Computational Biology and Bioinformatics 10 Geoff Margison Carcinogenesis 12 Karim Labib Cell Cycle 14 Iain Hagan Cell Division 16 Nic Jones
    [Show full text]
  • Life Changing Science
    LIFE CHANGING SCIENCE The Francis Crick Institute Annual Review 2017/18 AN INSTITUTE FOR DISCOVERY Our commitment to excellence, our emphasis on multidisciplinary research, our focus on young and emerging talent and our novel ways of partnership working are some of the factors that set the Crick apart. Front cover Vaccinia virus infection (green) disrupts a layer of epithelial cells (red/blue). Courtesy of Michael Way, Group Leader at the Crick. INTRODUCTION 2 Who we are Our year at a glance 2 Introduction by Paul Nurse 4 The Francis Crick Institute is a biomedical Progress against our strategy 6 discovery institute dedicated to understanding the RESEARCH HIGHLIGHTS 10 Cancer-causing mutation fundamental biology underlying health and disease. suppresses immune system 11 Our work is helping to build an understanding of Predicting lung cancer’s return 12 New understanding of human why disease develops and to translate discoveries embryo development 14 Chemical attraction could improve into new ways to prevent, diagnose and treat cancer immunotherapy 16 illnesses such as cancer, heart disease, stroke, Genes linked to malaria parasites’ persistence 17 infections and neurodegenerative diseases. Architecture of our ‘second brain’ 18 Cause of infertility side-stepped in mice 19 Mechanism for spinal cord development discovered 20 A new layer of complexity in embryo development 21 Two DNAs wedded with this ring 22 Unravelling how DNA gets copied 23 Telomerase’s dark side discovered 24 REVIEW OF THE YEAR 26 New group leaders arrive 27 Joined-up thinking 30 Focusing on the molecules of life 32 CryoEM at the Crick 34 Bringing academia and industry closer together 36 The people making research happen 38 Patterns in art and science 40 Rewarding research 42 Appointments 43 Supporting new discoveries 44 Our vision What’s inside Our vision is to be a world- We bring together outstanding scientists Science feature 32 leading multidisciplinary from all disciplines and carry out research Sophisticated microscopy is being biomedical research institute.
    [Show full text]
  • Charles Swanton MRCP Bsc Phd Fibiol
    Charles Swanton MRCP BSc PhD Biography Charles completed the MDPhD programme at University College London in 1999 having gained his PhD from the laboratory of Nic Jones at the Imperial Cancer Research Fund Laboratories establishing the subversion of cell cycle control by the Kaposi’s Sarcoma Herpesvirus encoded K-Cyclin (Swanton et al. Nature 1997) and was awarded the national Pontecorvo Imperial Cancer Research Fund PhD thesis award (Mann et al., 1999; Swanton et al., 1999; Swanton et al., 1997). Charles continued his interest in cell cycle disruption in cancer and its therapeutic applications (Swanton, Lancet Oncology 2004) and was made a Member of the Royal College of Physicians in 2003 and subsequently undertook his medical oncology training at the Royal Marsden Hospital. He was awarded a Cancer Research UK (CR-UK) clinician scientist fellowship in 2004 which allowed him to conduct his post-doctoral research training at the CR-UK London Research Institute with Prof Julian Downward, establishing multi-drug sensitivity mechanisms through RNA interference screening approaches, associated with paclitaxel and other common chemotherapy agents used in oncological practice (Swanton et al., 2007a; Swanton et al., 2007b). These screening datasets resulted in the observation that molecules that mediate chromosomal stability appeared to be significantly associated with those mediating taxane sensitivity and led to the first phase II clinical trial in colorectal cancer to attempt to define prospectively whether tumour chromosomal instability status alters response to a taxane-like drug. In 2008, Charles was awarded an MRC and a CR-UK senior clinical research fellowship and appointed MRC/CR-UK Group leader of the Translational Cancer Therapeutics Laboratory at the CRUK London Research Institute and Fellow of the Society of Biologists (FSB).
    [Show full text]
  • Cancer Research UK Gurdon Institute Prospectus 2020/2021 25 YEARS
    The Wellcome/ Cancer Research UK Gurdon Institute Prospectus 2020/2021 25 YEARS The Wellcome/ Cancer Research UK Gurdon Institute Studying Prospectus 2020/2021 E development to C U G E N D E R E R understand disease C HA R T The Gurdon Institute 3 Contents Welcome Welcome to our new Prospectus, where we highlight our Watermark, the first such award in the University. Special activities for - unusually - two years: 2019 and 2020. The thanks for this achievement go to Hélène Doerflinger, COVID-19 pandemic has made it an extraordinary time Phil Zegerman and Emma Rawlins. Director’s welcome 3 Emma Rawlins 38 for everyone. I want to express my pride and gratitude for the exceptional efforts of Institute members, After incubating Steve Jackson's company Adrestia in About the Institute 4 Daniel St Johnston 40 who have kept our building safe and our research the Institute for two years, we wished them well as they progressing; this applies especially to our core team, moved to the Babraham Research Campus. We also sent COVID stories 6 Ben Simons 42 whose dedication has been key to our best wishes to Meri Huch and our continued progress. As you will Rick Livesey and their labs, as they Highlights in 2019/2020 8 Azim Surani 44 see, there is much to be excited embarked on their new positions in about in our research and activities. Dresden and London, respectively. Focus on research Iva Tchasovnikarova 46 It was terrific to see Gurdon I'm delighted that Emma Rawlins Group leaders Fengzhu Xiong 48 members receive recognition for was promoted to Senior Group their achievements.
    [Show full text]
  • Breakthrough How Ideas Exchanged in the Canteen Can Lead to Research Discoveries
    News from the Medical Research Council network Summer 2013 100 years of life-changing discoveries The greatcoffee breakthrough How ideas exchanged in the canteen can lead to research discoveries. Discoveries of the century Well-known figures give us their thoughts on the biggest medical advances, past and future. Network can also be downloaded as a PDF at: www.mrc.ac.uk/network CONTENTS NEWS News COMMENT FROM A phenomenal legacy begins 3 A phenomenal John Informatics research centres launched across the UK 3 legacy begins Speedier access to brain tissue for research 5 Savill Universities and Science Minister David Willetts has officially opened the MRC-NIHR Phenome Centre CHIEF EXECUTIVE at Imperial College London, which will re-purpose some of the sophisticated technology from the Royal opening for new LMB building 5 The launch of four e-health London 2012 Olympics Anti-Doping Centre. informatics research centres (eHIRCs) and the UK informatics Unlike our genome, which collectively describes a person’s genetic material, the phenome describes all the other chemistry of our research network by the Science body. It is the product of how our genes and environment interact throughout development and life, and is analysed by linking our Minister in May (see opposite), chemical, metabolic and physiological features and responses. By measuring phenome patterns throughout life, researchers at the Latest discoveries marked part of a £90m total centre aim to identify the patterns which separate those who develop particular diseases from those who don’t. investment in so-called big data or Gout drug offers hope for heart disease patients 10 medical bioinformatics research– something we excel at here in The centre’s first three pilot studies are now underway.
    [Show full text]
  • November 2020 | YOUR IMPACT | LORD LEONARD and LADY ESTELLE WOLFSON FOUNDATION NOVEMBER 2020 YOUR IMPACT
    1 | November 2020 | YoUr ImPACT | LorD LEONArD AND LADY eSTeLLe WoLFSoN FoUNDATIoN NOVEMBER 2020 YOUR IMPACT PREPARED FOR THE LORD LEONARD AND LADY ESTELLE WOLFSON FOUNDATION Together we will beat cancer Sir Paul Nurse THANK YOU FOR YOUR SUPPORT Since opening its doors in November 2016, the Crick is establishing its reputation as one of the leading biomedical discovery research institutes in the world. So far, Crick scientists have produced more than 2,500 research publications, which are advancing our fundamental understanding of human health and disease. We are delighted to have your ongoing commitment to support Sir Paul Nurse and his team’s work to understand the intricate processes controlling the cell cycle. Here, we are pleased to present you with an update from Paul and his team in the Cell Cycle Laboratory, as well as a round-up of some of the pioneering advances that the Crick’s researchers have made over the past year. view from the 5th floor of the Francis Crick Institute HIGHLIGHTS AND ACHIEVEMENTS 2,500+ research papers have been published since the Crick opened, sharing new discoveries and AWARDS IN 2020 ideas that could transform the way we approach disease 12 early career group leaders Professor Sir Peter ratcliffe and Professor were appointed this past year, selected Charles Swanton were elected to join the from a pool of 371 applications submitted American Association for Cancer research from across the globe Academy in recognition of their significant The Crick is 5th in the world contributions to innovation and progress
    [Show full text]
  • Donation: the Lifeblood of the NHS
    News from the Medical Research Council Autumn 2018 network Leading science for better health Bl d donation: the lifeblood of the NHS Opinion: How secure data sharing can help us treat dementia Network can also be downloaded as a PDF at: mrc.ukri.org/network CONTENTS News COMMENT FROM Happy birthday to the NHS! 4 Health data: first UK snapshot review 5 Fiona Watt EXECUTIVE CHAIR People As the UK Research and Innovation Royal recognition for Nobel Prize-winner 9 Champion for Talent and Skills, I'm passionate about supporting researchers at the most pivotal points of their careers. It seems clear that we should be investing in Funding the best people, regardless of career stage and geography. £900m for future leaders 15 To help build expertise and opportunities for future careers, we're adding more activities to the list of those eligible to researchers employed on MRC grants, to cover activities that do not directly relate to their Latest discoveries specific research project. Potential therapy identified for common Supporting the career development of research staff is cause of dementia 16 equally important as supporting our researchers. That's why we've introduced a new 'research co-investigator' status for Eye drops with turmeric extract could research staff on MRC grants, to provide recognition for treat common eye disease 17 their intellectual research contributions and to help career development (see page 3). Sharing data and recognising individual research contributions are vital, especially for early-career Features researchers. I'm pleased to see the Dementias Platform UK leading the way with their data portal – a secure platform Blood donation: the lifeblood of the NHS 6 for sharing and analysing dementia research data.
    [Show full text]
  • Sir Bernard Katz (1911-2003): an Icon of Neurophysiology
    Curr Neurobiol 2018; 9(3): 101-105 ISSN 0975-9042 Sir Bernard Katz (1911-2003): An Icon of Neurophysiology Ronald P Rubin, PhD Department of Pharmacology & Toxicology, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York Abstract This article highlights the life and career of Sir Bernard Katz, a member of a generation of eminent physiologists who was a refugee from the Third Reich. Despite setbacks incurred by anti- Semitism early in life, Katz had the tenacity to achieve fulfillment in his extraordinary career. With the support of the eminent A.V. Hill, who had a pivotal influence on his life and career, Katz conducted research at University College London mainly in the 1950’s and 60’s. His work included the study of miniature end-plate potentials, quantal secretion of neurotransmitters, the role of calcium in transmitter release, and the postsynaptic action of acetylcholine. In addition, his department was a center for pre- and postdoctoral students from all over the world and his influence on the training of a large number of the world’s most prominent neurophysiologist was monumental. Because Bernard Katz’s work remains the basis of our understanding of the release and actions of neurotransmitters, he was awarded the Nobel Prize in 1970. Keywords: Bernard Katz, Neuromuscular Junction, Quantal release, End-Plate potential. Early Years After the Russian revolution of 1917, the members of the Katz family- along with other Russian expatriates- lost their Sir Bernard Katz was one of the generation of distinguished nationality and became stateless.
    [Show full text]